Protagonist Therapeutics (PTGX) Equity Average (2016 - 2026)

Protagonist Therapeutics has disclosed Equity Average across 11 years of filings, most recently posting $635.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $635.1 million, down 6.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $635.1 million (down 6.9% YoY), and the FY2025 annual result was $645.0 million, up 27.47% from the prior year.
• Equity Average came in at $635.1 million for Q1 2026 at Protagonist Therapeutics, up from $630.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $682.2 million in Q1 2025 to a low of $215.9 million in Q1 2023.
• The 5-year median for Equity Average is $448.6 million (2024), against an average of $446.0 million.
• Across the five-year window, Equity Average retreated 28.25% in 2023 and surged 115.93% in 2024, its largest moves.
• Protagonist Therapeutics' Equity Average stood at $229.6 million in 2022, then surged by 39.11% to $319.4 million in 2023, then surged by 88.97% to $603.6 million in 2024, then rose by 4.38% to $630.1 million in 2025, then gained by 0.8% to $635.1 million in 2026.
• The last three Equity Average figures came in at $635.1 million (Q1 2026), $630.1 million (Q4 2025), and $656.7 million (Q3 2025), per Business Quant data.